Best High Tech Stocks To Own For 2019

tags:ZIOP,PMT,TX,EVHC,INVA,IOSP,

Gevo (NASDAQ:GEVO) was upgraded by equities research analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on GEVO. Zacks Investment Research upgraded Gevo from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. HC Wainwright reiterated a “hold” rating on shares of Gevo in a research note on Tuesday, May 15th.

Get Gevo alerts:

NASDAQ:GEVO traded up $4.00 during trading hours on Friday, reaching $4.23. 4,411 shares of the company were exchanged, compared to its average volume of 582,213. The company has a market capitalization of $5.57 million, a P/E ratio of -0.14 and a beta of 2.25. Gevo has a 1-year low of $0.19 and a 1-year high of $0.96. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.82 and a quick ratio of 1.23.

Best High Tech Stocks To Own For 2019: ZIOPHARM Oncology Inc(ZIOP)

Advisors' Opinion:

• [By Lisa Levin] Gainers Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study. Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing. ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating. Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook. TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy. Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday. Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital. Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00. SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday. Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40. Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins. Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr
• [By Keith Speights]

  Ziopharm Oncology Inc. (NASDAQ:ZIOP) shareholders have been on a roller coaster ride this year. The stock soared 16% in May, but the ride promptly went downhill in June, with the biotech's share price dropping more than 10%. The first four months of 2018 featured more of the same up-and-down action.

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers Stellar Biotechnologies, Inc. (NASDAQ: SBOT) fell 42 percent to $2.25 in pre-market trading after dropping 31.45 percent on Thursday. Stellar Biotechnologies priced 2.075 million units at price of $2.65 per unit. Symantec Corporation (NASDAQ: SYMC) shares fell 25.2 percent to $21.82 in pre-market trading. Symantec reported better-than-expected earnings for its fourth quarter, but issued weak second-quarter guidance. AGM Group Holdings Inc. (NASDAQ: AGMH) shares fell 9.5 percent to $10 in pre-market trading after surging 7.79 percent on Thursday. ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) fell 8.9 percent to $4.11 in pre-market trading after the company posted wider-than-expected Q1 loss. Redfin Corporation (NASDAQ: RDFN) fell 8.6 percent to $21.00 in pre-market trading after reporting Q1 results. Geron Corporation (NASDAQ: GERN) fell 8.3 percent to $3.33 in pre-market trading. Geron posted a Q1 loss of $0.04 per share. Talend S.A. (NASDAQ: TLND) shares fell 6 percent to $56 in pre-market trading after reporting Q1 results. Flotek Industries, Inc. (NYSE: FTK) fell 5.4 percent to $3.54 in pre-market trading after dropping 2.35 percent on Thursday. Halozyme Therapeutics, Inc. (NASDAQ: HALO) fell 5.1 percent to $18.95 in pre-market trading after reporting Q1 results. Yelp Inc. (NYSE: YELP) shares fell 4.9 percent to $45.40 in pre-market trading. Yelp reported stronger-than-expected results for its first quarter on Thursday. Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares fell 3.3 percent to $7.50 in pre-market trading after dropping 4.32 percent on Thursday
• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Ziopharm Oncology (ZIOP)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Todd Campbell]

  After disclosing that the Food and Drug Administration is asking for more information before signing off on a phase 1 study of its "Sleeping Beauty" CAR-T for leukemia and lymphoma, shares in Ziopharm Oncology (NASDAQ:ZIOP) were tumbling 17.7% at 3 p.m. EDT today.

Best High Tech Stocks To Own For 2019: PennyMac Mortgage Investment Trust(PMT)

Advisors' Opinion:

• [By Stephan Byrd]

  Pennymac Mortgage Investment (NYSE:PMT) – Equities researchers at Wedbush lifted their Q1 2019 earnings per share estimates for shares of Pennymac Mortgage Investment in a research note issued to investors on Thursday, May 10th. Wedbush analyst J. Weaver now anticipates that the real estate investment trust will post earnings per share of $0.36 for the quarter, up from their previous estimate of $0.34. Wedbush also issued estimates for Pennymac Mortgage Investment’s Q2 2019 earnings at $0.43 EPS, Q3 2019 earnings at $0.43 EPS, Q4 2019 earnings at $0.52 EPS and FY2019 earnings at $1.74 EPS.

• [By Stephan Byrd]

  Pennymac Mortgage Investment (NYSE:PMT) shares reached a new 52-week high and low on Monday . The company traded as low as $18.60 and last traded at $18.62, with a volume of 19306 shares changing hands. The stock had previously closed at $18.50.

Best High Tech Stocks To Own For 2019: Ternium S.A.(TX)

Advisors' Opinion:

• [By Logan Wallace]

  TT International cut its position in Ternium (NYSE:TX) by 24.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 865,613 shares of the basic materials company’s stock after selling 277,967 shares during the quarter. Ternium makes up about 1.2% of TT International’s holdings, making the stock its 10th biggest position. TT International owned about 0.43% of Ternium worth $28,123,000 at the end of the most recent reporting period.

• [By Lisa Levin] Gainers Genprex, Inc. (NASDAQ: GNPX) shares gained 86.76 percent to close at $11.00 on Thursday. Comstock Resources, Inc. (NYSE: CRK) shares climbed 47.06 percent to close at $7.00 after the company disclosed a deal with Arkoma Drilling L.P. and Williston Drilling, L.P. to buy oil & gas properties in North Dakota. Comstock announced withdrawal of tender offers for outstanding secured notes. Ceridian HCM Holding Inc. (NASDAQ: CDAY) gained 41.86 percent to close at $31.21. MarineMax, Inc. (NYSE: HZO) shares rose 26.5 percent to close at $22.20 as the company posted upbeat Q2 results and raised its FY18 outlook. Concord Medical Services Holdings Limited (NYSE: CCM) jumped 24.92 percent to close at $4.06. Mattersight Corporation (NASDAQ: MATR) shares climbed 23.26 percent to close at $2.65 after the company agreed to be purchased by NICE Ltd. Chipotle Mexican Grill, Inc. (NYSE: CMG) rose 24.44 percent to close at $422.50 as the company reported stronger-than-expected results for its first quarter on Wednesday. Ultra Clean Holdings, Inc. (NASDAQ: UCTT) gained 17.75 percent to close at $18.64 following upbeat Q1 earnings. PCM, Inc. (NASDAQ: PCMI) rose 16.59 percent to close at $12.30 following Q1 results. Zymeworks Inc. (NASDAQ: ZYME) rose 16.06 percent to close at $15.25. Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) shares climbed 14.5 percent to close at $121.42 as the company posted reported Q1 beat And raised FY18 outlook. Advanced Micro Devices, Inc. (NASDAQ: AMD) shares gained 13.7 percent to close at $11.04 as the company reported upbeat results for its first quarter. Axsome Therapeutics, Inc. (NASDAQ: AXSM) rose 13.21 percent to close at $3.00 after the company disclosed a positive outcome of the interim analysis of STRIDE-1 Phase 3 trial of AXS-05 in treatment resistant depression. O'Reilly Automotive, Inc. (NASDAQ: ORLY) jumped 13.06 percent to close at $257.40 following upbeat Q1 profit. BioTelemetry,
• [By Logan Wallace]

  Sumitomo (OTCMKTS: SSUMY) and Ternium (NYSE:TX) are both multi-sector conglomerates companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Best High Tech Stocks To Own For 2019: Envision Healthcare Holdings, Inc.(EVHC)

Advisors' Opinion:

• [By Tim Melvin]

  I'm talking about private equity behemoth KKR & Co. LP (NYSE: KKR) buying Envision Healthcare Corp. (NYSE: EVHC) for $5.7 billion in cash, with the total deal value adding up to $9.9 billion including debt. This marks one of the largest leveraged buyouts of 2018.

• [By Logan Wallace]

  Royal Bank of Canada lowered shares of Envision Healthcare (NYSE:EVHC) from an outperform rating to a sector perform rating in a research report released on Tuesday.

• [By Money Morning Staff Reports]

  This was not overlooked by Wall Street, either, as the giant private equity firm KKR & Co. LP (NYSE: KKR) bought Envision Healthcare Corp. (NYSE: EVHC) for $5.7 billion in cash, with the total deal value adding up to $9.9 billion including debt. It was one of the largest leveraged buyouts so far in 2018.

Best High Tech Stocks To Own For 2019: Innoviva, Inc. (INVA)

Advisors' Opinion:

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  With this in mind, we asked three Motley Fool investors to name one healthcare stock that's tops on their list for the month of June. These three mid-cap stocks made the cut: royalty drug company Innoviva (NASDAQ:INVA), mental illness treatment center operator Acadia Healthcare (NASDAQ:ACHC), and health savings account provider HealthEquity (NASDAQ:HQY).

• [By Sean Williams]

  Lastly, there's Innoviva (NASDAQ:INVA), which isn't a traditional drug stock, per se. Innoviva is a royalty company that's currently reaping benefits from a group of long-lasting COPD and asthma medications that were developed in cooperation with GlaxoSmithKline (NYSE:GSK). You know these medicines today as Breo Ellipta and Anoro Ellipta, to name a few.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Innoviva (INVA)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best High Tech Stocks To Own For 2019: Innospec Inc.(IOSP)

Advisors' Opinion:

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Innospec (IOSP)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  TRADEMARK VIOLATION NOTICE: “TIAA CREF Investment Management LLC Has $7.35 Million Holdings in Innospec (IOSP)” was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3353526/tiaa-cref-investment-management-llc-has-7-35-million-holdings-in-innospec-iosp.html.

• [By Max Byerly]

  Innospec (NASDAQ:IOSP) last issued its quarterly earnings data on Tuesday, February 13th. The specialty chemicals company reported $1.47 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.34. Innospec had a net margin of 4.73% and a return on equity of 15.57%. The business had revenue of $353.80 million during the quarter. analysts expect that Innospec will post 4.3 earnings per share for the current year.

  COPYRIGHT VIOLATION NOTICE: “Innospec (IOSP) Given Consensus Recommendation of “Hold” by Brokerages” was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3368568/innospec-iosp-given-consensus-recommendation-of-hold-by-brokerages.html.

  Innospec Company Profile

• [By Logan Wallace]

  Press coverage about Innospec (NASDAQ:IOSP) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innospec earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned media stories about the specialty chemicals company an impact score of 46.0007935851604 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

• [By Shane Hupp]

  Innospec (NASDAQ: IOSP) and JOHNSON MATTHEY/S (OTCMKTS:JMPLY) are both basic materials companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

• [By Stephan Byrd]

  Innospec (NASDAQ:IOSP) insider Philip Curran sold 2,000 shares of Innospec stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $73.63, for a total transaction of $147,260.00. Following the completion of the transaction, the insider now directly owns 4,218 shares in the company, valued at approximately $310,571.34. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Google might return to China. Here's why that's controversial

Google is reportedly planning to get back into China, a lucrative market where it has a long history of tangling with authorities.

The Intercept reported Wednesday that Google plans to launch a search app in China that would block sensitive websites and search terms to comply with Chinese government censorship.

China has hundreds of millions of internet users and a thriving online shopping market, making it impossible for US tech companies to ignore. But jumping back into China presents ethical issues for Google (GOOGL), which has long advocated a free and open internet.

Andy Tian, a tech executive who formerly led mobile strategy and partnerships for Google in China, said the Chinese tech companies that currently dominate search can't compete with Google's product.

"There's a huge void, Google can fill that void," said Tian, who is now CEO of Asia Innovations.

Asked about The Intercept report, Google said in a statement that "we don't comment on speculation about future plans."

Like many other US internet platforms, Google's most popular products �� search, YouTube, Gmail �� have been banned in China for years, blacked out by a vast government censorship apparatus known as the Great Firewall.

But that wasn't always the case.

Google China 1.0

Google launched a Chinese language version of its search engine �� google.cn �� in 2006. It complied with Beijing's censorship laws.

"While removing search results is inconsistent with Google's mission, providing no information (or a heavily degraded user experience that amounts to no information) is more inconsistent with our mission," Google said at the time.

While the search engine was censored, it also flagged to users when information was removed from results. That gave Chinese internet users an idea of what they were not allowed to see.

China blocks Google searches on the eve of the Tiananmen Square massacre in 2014.

"We reminded users in China every single day that they are looking at filtered results," said Tian, who worked at Google when the search engine launched.

Still, critics complained that Google was breaching its own company motto: "Don't Be Evil."

The company's devotion to web freedom, critics charged, was being subverted by a willingness to comply with Chinese censorship in return for access to a huge potential customer base.

Attack and retreat

Google was battling Baidu (BIDU) for market share. Three years after launch, Google had wrestled about a third of the search market away from its Chinese rival.

The dynamic changed in January 2010, when Google charged that Chinese hackers had targeted Google and more than 20 other Western companies and compromised the email accounts of Chinese dissidents living abroad.

Beijing denied that it had been involved in the attacks, but the incident sparked a political fight with Washington.

A laptop screen displaying the landing page google.cn, which linked to an uncensored Hong Kong site on July 1, 2010, in Beijing.

About three months later, Google made good on a threat to stop offering search in China.

In March 2010, it announced it had stopped running the censored Google.cn service and began routing its Chinese users to an uncensored version of Google based in Hong Kong.

Academics, university students and other researchers relied heavily on Google's search services to access information not available through Chinese search engines like Baidu.

Businesses that depended on Google applications such as Google Docs and Gmail also suffered.

Google wants back behind the Firewall

Google's parent company Alphabet changed its motto in 2015, replacing "Don't Be Evil" with "Do the Right Thing."

From a business perspective, getting back into China is the right thing for Google. It currently offers just a few services in the country �� Google Translate, a file organizing program and a new AI game.

Advertising is Google's main source of revenue, and 1.4 billion potential users are hard to ignore. Facebook (FB), which competes with Google for advertising revenue, is also locked out of China.

Shares in Baidu (BIDU) dropped 8% on Wednesday after The Intercept report was published.

Critics and human rights groups are already accusing Google of bending to China's will.

"The reality is that they will be serving the Chinese government," said Lockman Tsui, former head of free expression for Google in Asia.

"The government now tracks people, apps on phones reveal who you are, where you are. They are intrusive," he added. "They collect much more data and Google can be requested to handover these data to the government."

�� Begona Blanco Munoz contributed reporting.

Brokerages Set Marsh & McLennan Companies, Inc. (MMC) PT at $91.86

Marsh & McLennan Companies, Inc. (NYSE:MMC) has received an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $91.86.

A number of research analysts have commented on the company. Citigroup boosted their target price on Marsh & McLennan Companies from $94.00 to $97.00 and gave the company a “buy” rating in a research note on Thursday, July 12th. Zacks Investment Research downgraded Marsh & McLennan Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 4th.

Get Marsh & McLennan Companies alerts:

Several institutional investors and hedge funds have recently added to or reduced their stakes in MMC. Artisan Partners Limited Partnership lifted its position in shares of Marsh & McLennan Companies by 3.8% during the 1st quarter. Artisan Partners Limited Partnership now owns 7,851,174 shares of the financial services provider’s stock worth $648,428,000 after purchasing an additional 287,978 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Marsh & McLennan Companies by 22.5% during the 1st quarter. JPMorgan Chase & Co. now owns 5,322,464 shares of the financial services provider’s stock worth $439,582,000 after purchasing an additional 976,003 shares during the last quarter. OppenheimerFunds Inc. lifted its position in shares of Marsh & McLennan Companies by 10.5% during the 1st quarter. OppenheimerFunds Inc. now owns 3,609,298 shares of the financial services provider’s stock worth $298,093,000 after purchasing an additional 342,211 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Marsh & McLennan Companies by 155.0% during the 1st quarter. American Century Companies Inc. now owns 2,822,249 shares of the financial services provider’s stock worth $233,090,000 after purchasing an additional 1,715,497 shares during the last quarter. Finally, Mawer Investment Management Ltd. lifted its position in shares of Marsh & McLennan Companies by 1.2% during the 1st quarter. Mawer Investment Management Ltd. now owns 2,810,468 shares of the financial services provider’s stock worth $232,071,000 after purchasing an additional 32,203 shares during the last quarter. Institutional investors own 85.06% of the company’s stock.

NYSE MMC traded up $0.35 on Friday, reaching $87.48. The stock had a trading volume of 1,357,426 shares, compared to its average volume of 1,817,835. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.52. Marsh & McLennan Companies has a 1 year low of $76.68 and a 1 year high of $87.89. The company has a market capitalization of $44.21 billion, a P/E ratio of 22.32, a price-to-earnings-growth ratio of 1.61 and a beta of 0.96.

Marsh & McLennan Companies (NYSE:MMC) last issued its earnings results on Thursday, April 26th. The financial services provider reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.08. Marsh & McLennan Companies had a return on equity of 29.38% and a net margin of 11.11%. The firm had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.87 billion. During the same quarter in the previous year, the company posted $1.08 earnings per share. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. equities analysts anticipate that Marsh & McLennan Companies will post 4.33 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, August 15th. Stockholders of record on Wednesday, July 11th will be paid a dividend of $0.415 per share. This represents a $1.66 annualized dividend and a dividend yield of 1.90%. The ex-dividend date is Tuesday, July 10th. This is an increase from Marsh & McLennan Companies’s previous quarterly dividend of $0.38. Marsh & McLennan Companies’s dividend payout ratio is 42.35%.

Marsh & McLennan Companies Company Profile

Marsh & McLennan Companies, Inc, a professional services firm, provides advice and solutions in the areas of risk, strategy, and people worldwide. It operates in two segments, Risk and Insurance Services, and Consulting. The Risk and Insurance Services segment offers risk management services, such as risk advice, risk transfer, and risk control and mitigation solutions, as well as insurance, reinsurance broking, catastrophe and financial modeling, and related advisory services.

Featured Story: Relative Strength Index